CA2690776A1 - Complexes medicamenteux acides de glucosamine exempts d'halogenure - Google Patents
Complexes medicamenteux acides de glucosamine exempts d'halogenure Download PDFInfo
- Publication number
- CA2690776A1 CA2690776A1 CA2690776A CA2690776A CA2690776A1 CA 2690776 A1 CA2690776 A1 CA 2690776A1 CA 2690776 A CA2690776 A CA 2690776A CA 2690776 A CA2690776 A CA 2690776A CA 2690776 A1 CA2690776 A1 CA 2690776A1
- Authority
- CA
- Canada
- Prior art keywords
- complex
- copolymers
- homopolymers
- glucosamine
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940079593 drug Drugs 0.000 title claims description 32
- 239000003814 drug Substances 0.000 title claims description 32
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 65
- 229960002442 glucosamine Drugs 0.000 claims abstract description 65
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 63
- 229920001519 homopolymer Polymers 0.000 claims abstract description 39
- 229920001577 copolymer Polymers 0.000 claims abstract description 36
- 229920000642 polymer Polymers 0.000 claims abstract description 36
- 229940126585 therapeutic drug Drugs 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 150000004820 halides Chemical class 0.000 claims abstract description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 6
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 6
- 239000011248 coating agent Substances 0.000 claims abstract description 6
- 238000000576 coating method Methods 0.000 claims abstract description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 6
- 229940096529 carboxypolymethylene Drugs 0.000 claims abstract description 5
- 150000004676 glycans Chemical class 0.000 claims abstract description 5
- 229920002401 polyacrylamide Polymers 0.000 claims abstract description 5
- 239000004584 polyacrylic acid Substances 0.000 claims abstract description 5
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 5
- 239000005017 polysaccharide Substances 0.000 claims abstract description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 5
- 229940069328 povidone Drugs 0.000 claims abstract description 5
- 239000000048 adrenergic agonist Substances 0.000 claims abstract description 4
- 230000000578 anorexic effect Effects 0.000 claims abstract description 4
- 239000000730 antalgic agent Substances 0.000 claims abstract description 4
- 230000003288 anthiarrhythmic effect Effects 0.000 claims abstract description 4
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 4
- 230000003266 anti-allergic effect Effects 0.000 claims abstract description 4
- 230000003257 anti-anginal effect Effects 0.000 claims abstract description 4
- 230000001088 anti-asthma Effects 0.000 claims abstract description 4
- 230000003178 anti-diabetic effect Effects 0.000 claims abstract description 4
- 230000001387 anti-histamine Effects 0.000 claims abstract description 4
- 230000002460 anti-migrenic effect Effects 0.000 claims abstract description 4
- 230000000118 anti-neoplastic effect Effects 0.000 claims abstract description 4
- 230000000648 anti-parkinson Effects 0.000 claims abstract description 4
- 230000001754 anti-pyretic effect Effects 0.000 claims abstract description 4
- 230000002785 anti-thrombosis Effects 0.000 claims abstract description 4
- 230000000767 anti-ulcer Effects 0.000 claims abstract description 4
- 239000000043 antiallergic agent Substances 0.000 claims abstract description 4
- 229940124345 antianginal agent Drugs 0.000 claims abstract description 4
- 239000003416 antiarrhythmic agent Substances 0.000 claims abstract description 4
- 239000000924 antiasthmatic agent Substances 0.000 claims abstract description 4
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 4
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 4
- 229940125681 anticonvulsant agent Drugs 0.000 claims abstract description 4
- 239000001961 anticonvulsive agent Substances 0.000 claims abstract description 4
- 239000000935 antidepressant agent Substances 0.000 claims abstract description 4
- 229940005513 antidepressants Drugs 0.000 claims abstract description 4
- 239000000739 antihistaminic agent Substances 0.000 claims abstract description 4
- 229940125715 antihistaminic agent Drugs 0.000 claims abstract description 4
- 229940030600 antihypertensive agent Drugs 0.000 claims abstract description 4
- 239000002220 antihypertensive agent Substances 0.000 claims abstract description 4
- 229940034982 antineoplastic agent Drugs 0.000 claims abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 4
- 239000000939 antiparkinson agent Substances 0.000 claims abstract description 4
- 239000000164 antipsychotic agent Substances 0.000 claims abstract description 4
- 229940005529 antipsychotics Drugs 0.000 claims abstract description 4
- 239000002221 antipyretic Substances 0.000 claims abstract description 4
- 229940125716 antipyretic agent Drugs 0.000 claims abstract description 4
- 229940124575 antispasmodic agent Drugs 0.000 claims abstract description 4
- 229960004676 antithrombotic agent Drugs 0.000 claims abstract description 4
- 239000002249 anxiolytic agent Substances 0.000 claims abstract description 4
- 230000000949 anxiolytic effect Effects 0.000 claims abstract description 4
- 229940005530 anxiolytics Drugs 0.000 claims abstract description 4
- 239000000850 decongestant Substances 0.000 claims abstract description 4
- 229940124581 decongestants Drugs 0.000 claims abstract description 4
- 206010061428 decreased appetite Diseases 0.000 claims abstract description 4
- 239000002934 diuretic Substances 0.000 claims abstract description 4
- 229940030606 diuretics Drugs 0.000 claims abstract description 4
- 230000003533 narcotic effect Effects 0.000 claims abstract description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract description 4
- 229940125723 sedative agent Drugs 0.000 claims abstract description 4
- 239000000932 sedative agent Substances 0.000 claims abstract description 4
- 229940124549 vasodilator Drugs 0.000 claims abstract description 4
- 239000003071 vasodilator agent Substances 0.000 claims abstract description 4
- 239000011541 reaction mixture Substances 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- -1 protoprophyrin IX Chemical compound 0.000 claims description 13
- 238000004108 freeze drying Methods 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 9
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 8
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 6
- 229960001680 ibuprofen Drugs 0.000 claims description 6
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 claims description 6
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 5
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 5
- 229960003529 diazepam Drugs 0.000 claims description 5
- 229960001259 diclofenac Drugs 0.000 claims description 5
- 229960000905 indomethacin Drugs 0.000 claims description 5
- 229960002009 naproxen Drugs 0.000 claims description 5
- 229960002036 phenytoin Drugs 0.000 claims description 5
- 229920001451 polypropylene glycol Polymers 0.000 claims description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 4
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 4
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 4
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 4
- 229960000991 ketoprofen Drugs 0.000 claims description 4
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 4
- 229960005489 paracetamol Drugs 0.000 claims description 4
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 claims description 3
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 claims description 3
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 3
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims description 3
- DVNYTAVYBRSTGK-UHFFFAOYSA-N 5-aminoimidazole-4-carboxamide Chemical compound NC(=O)C=1N=CNC=1N DVNYTAVYBRSTGK-UHFFFAOYSA-N 0.000 claims description 3
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 3
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims description 3
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims description 3
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 claims description 3
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 claims description 3
- 108010058907 Tiopronin Proteins 0.000 claims description 3
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 claims description 3
- MUXFZBHBYYYLTH-UHFFFAOYSA-N Zaltoprofen Chemical compound O=C1CC2=CC(C(C(O)=O)C)=CC=C2SC2=CC=CC=C21 MUXFZBHBYYYLTH-UHFFFAOYSA-N 0.000 claims description 3
- 229960000571 acetazolamide Drugs 0.000 claims description 3
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 claims description 3
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 3
- 229960000723 ampicillin Drugs 0.000 claims description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 3
- LSNWBKACGXCGAJ-UHFFFAOYSA-N ampiroxicam Chemical compound CN1S(=O)(=O)C2=CC=CC=C2C(OC(C)OC(=O)OCC)=C1C(=O)NC1=CC=CC=N1 LSNWBKACGXCGAJ-UHFFFAOYSA-N 0.000 claims description 3
- 229950011249 ampiroxicam Drugs 0.000 claims description 3
- 230000002921 anti-spasmodic effect Effects 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960003655 bromfenac Drugs 0.000 claims description 3
- 229960003184 carprofen Drugs 0.000 claims description 3
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 claims description 3
- 229960000590 celecoxib Drugs 0.000 claims description 3
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 3
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 claims description 3
- 229960001803 cetirizine Drugs 0.000 claims description 3
- 229960002155 chlorothiazide Drugs 0.000 claims description 3
- 229960001761 chlorpropamide Drugs 0.000 claims description 3
- 229960003405 ciprofloxacin Drugs 0.000 claims description 3
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 claims description 3
- 229960003199 etacrynic acid Drugs 0.000 claims description 3
- 229960004369 flufenamic acid Drugs 0.000 claims description 3
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims description 3
- 229960003883 furosemide Drugs 0.000 claims description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 3
- 229960004187 indoprofen Drugs 0.000 claims description 3
- 229960004502 levodopa Drugs 0.000 claims description 3
- 235000019136 lipoic acid Nutrition 0.000 claims description 3
- 229960003803 meclofenamic acid Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 229950010911 orazamide Drugs 0.000 claims description 3
- 229960001639 penicillamine Drugs 0.000 claims description 3
- 229960001412 pentobarbital Drugs 0.000 claims description 3
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 3
- 229960002695 phenobarbital Drugs 0.000 claims description 3
- 229960002702 piroxicam Drugs 0.000 claims description 3
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 3
- 229960002662 propylthiouracil Drugs 0.000 claims description 3
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 3
- 229960000371 rofecoxib Drugs 0.000 claims description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 3
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960004306 sulfadiazine Drugs 0.000 claims description 3
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 claims description 3
- 229960002211 sulfapyridine Drugs 0.000 claims description 3
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims description 3
- 229960000894 sulindac Drugs 0.000 claims description 3
- 229960000278 theophylline Drugs 0.000 claims description 3
- 229960002663 thioctic acid Drugs 0.000 claims description 3
- DZLNHFMRPBPULJ-UHFFFAOYSA-N thioproline Chemical compound OC(=O)C1CSCN1 DZLNHFMRPBPULJ-UHFFFAOYSA-N 0.000 claims description 3
- 229950001139 timonacic Drugs 0.000 claims description 3
- 229960004402 tiopronin Drugs 0.000 claims description 3
- 229960005371 tolbutamide Drugs 0.000 claims description 3
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 claims description 3
- 229960002905 tolfenamic acid Drugs 0.000 claims description 3
- 229960001017 tolmetin Drugs 0.000 claims description 3
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims description 3
- 229960005080 warfarin Drugs 0.000 claims description 3
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims description 3
- 229950004227 zaltoprofen Drugs 0.000 claims description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 230000002378 acidificating effect Effects 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 229910052744 lithium Inorganic materials 0.000 description 9
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000000087 stabilizing effect Effects 0.000 description 5
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 150000003462 sulfoxides Chemical group 0.000 description 3
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- RFIMISVNSAUMBU-UHFFFAOYSA-N 2-(hydroxymethyl)-2-(prop-2-enoxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC=C RFIMISVNSAUMBU-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229960002849 glucosamine sulfate Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- CAOFVLJHCHGTGE-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydroiodide Chemical compound I.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CAOFVLJHCHGTGE-BTVCFUMJSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150013124 Plce1 gene Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 150000004263 amino monosaccharides Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- JILPJDVXYVTZDQ-UHFFFAOYSA-N lithium methoxide Chemical compound [Li+].[O-]C JILPJDVXYVTZDQ-UHFFFAOYSA-N 0.000 description 1
- AZVCGYPLLBEUNV-UHFFFAOYSA-N lithium;ethanolate Chemical compound [Li+].CC[O-] AZVCGYPLLBEUNV-UHFFFAOYSA-N 0.000 description 1
- HAUKUGBTJXWQMF-UHFFFAOYSA-N lithium;propan-2-olate Chemical compound [Li+].CC(C)[O-] HAUKUGBTJXWQMF-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
- C07H5/06—Aminosugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2007/014610 WO2009002297A1 (fr) | 2007-06-22 | 2007-06-22 | Complexes medicamenteux acides de glucosamine exempts d'halogenure |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2690776A1 true CA2690776A1 (fr) | 2008-12-31 |
Family
ID=40185904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2690776A Abandoned CA2690776A1 (fr) | 2007-06-22 | 2007-06-22 | Complexes medicamenteux acides de glucosamine exempts d'halogenure |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2190853A4 (fr) |
CA (1) | CA2690776A1 (fr) |
WO (1) | WO2009002297A1 (fr) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2413535B1 (fr) | 2010-07-30 | 2012-09-19 | Deutsche Telekom AG | Procédé d'estimation du type de structure de groupe d'images de plusieurs trames vidéo dans un flux vidéo |
WO2014037832A2 (fr) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions et méthodes de traitement de l'épilepsie et de maladies neurologiques |
CN104603096A (zh) | 2012-05-07 | 2015-05-06 | 塞利克斯比奥私人有限公司 | 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法 |
SG11201407300VA (en) | 2012-05-07 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of neurological disorders |
WO2013167990A1 (fr) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions et méthodes de traitement de la dépression |
US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
WO2013167992A1 (fr) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions et méthodes de traitement de troubles inflammatoires |
US20150148306A1 (en) * | 2012-05-08 | 2015-05-28 | Mahesh Kandula | Compositions and methods for the treatment of inflammation |
WO2013167993A1 (fr) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions et méthodes de traitement de troubles neurologiques dégénératifs |
WO2013168025A1 (fr) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions et méthodes de traitement des maladies de coagulation du sang |
US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
WO2013168005A2 (fr) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions et méthodes de traitement du syndrome des jambes sans repos et de la fibromyalgie |
US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
WO2013168015A1 (fr) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions et méthodes pour le traitement de l'asthme et de l'allergie |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
WO2013168033A1 (fr) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions et methodes pour le traitement de maladies neurologiques |
WO2013168016A1 (fr) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions et méthodes de traitement du syndrome métabolique |
WO2013168012A1 (fr) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions et méthodes de traitement de troubles respiratoires |
WO2013168000A1 (fr) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions et méthodes de traitement de la douleur sévère |
WO2013168002A1 (fr) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions et méthodes de traitement d'affections neurologiques |
CA2873098A1 (fr) | 2012-05-23 | 2013-11-28 | Cellixbio Private Limited | Compositions et methodes pour le traitement de la sclerose en plaques |
CN104603100A (zh) | 2012-05-23 | 2015-05-06 | 塞利克斯比奥私人有限公司 | 用于治疗炎症性肠病的组合物和方法 |
WO2013175347A2 (fr) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions et méthodes pour le traitement de troubles respiratoires |
SG11201407326XA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of mucositis |
WO2013175344A2 (fr) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions et méthodes pour le traitement de la parodontite et de la polyarthrite rhumatoïde |
WO2013175376A2 (fr) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions et méthodes de traitement de la douleur locale |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
WO2014037833A2 (fr) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions et méthodes de traitement d'une inflammation et de troubles lipidiques |
US9670153B2 (en) | 2012-09-08 | 2017-06-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
CA2800056A1 (fr) | 2012-12-24 | 2014-06-24 | Nova Chemicals Corporation | Compositions de melange de polyethylene |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
AU2014276346A1 (en) | 2013-06-04 | 2015-12-24 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
WO2016110865A1 (fr) | 2015-01-06 | 2016-07-14 | Cellix Bio Private Limited | Compositions et méthodes pour le traitement d'une inflammation et de la douleur |
WO2016046835A1 (fr) | 2014-09-26 | 2016-03-31 | Cellix Bio Private Limited | Compositions et méthodes de traitement de l'épilepsie et de troubles neurologiques |
WO2016051420A1 (fr) | 2014-09-29 | 2016-04-07 | Cellix Bio Private Limited | Compositions et méthodes pour le traitement de la sclérose en plaques |
EP3212626B1 (fr) | 2014-10-27 | 2018-11-07 | Cellix Bio Private Limited | Séls á trois composants du ester monométhylique du acid fumarique avec pipérazine ou ethylene diamine pour le traitement de sclérose en plaques |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUT59692A (en) * | 1990-11-15 | 1992-06-29 | Puetter Medice Chem Pharm | Process for producing complexes containing s/+/-phenyl-alkanoic acids and aminosugars |
CA2293605A1 (fr) * | 1998-04-11 | 1999-10-21 | Paolo Luca Maria Giorgetti | Preparations pharmaceutiques a base de sels de ketoprofene hydrosoluble et applications correspondantes |
US6472380B1 (en) * | 1999-11-24 | 2002-10-29 | Jame Fine Chemicals, Inc. | Glucosamine sulfate calcium chloride composition and processes for the preparation of glucosamine sulfate metal chlorides |
US20070003621A1 (en) * | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Dosage forms for movement disorder treatment |
-
2007
- 2007-06-22 EP EP07835861A patent/EP2190853A4/fr not_active Withdrawn
- 2007-06-22 CA CA2690776A patent/CA2690776A1/fr not_active Abandoned
- 2007-06-22 WO PCT/US2007/014610 patent/WO2009002297A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP2190853A1 (fr) | 2010-06-02 |
EP2190853A4 (fr) | 2011-08-31 |
WO2009002297A1 (fr) | 2008-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2690776A1 (fr) | Complexes medicamenteux acides de glucosamine exempts d'halogenure | |
Yilmaz | Chitosan: a versatile biomaterial | |
Yan et al. | Preparation of N-succinyl-chitosan and their physical-chemical properties as a novel excipient | |
US20200054565A1 (en) | Monolithic tablets based on carboxyl polymeric complexes for controlled drug release | |
MX351855B (es) | Composicion farmaceutica para liberacion modificada. | |
JP2007153944A (ja) | カチオン化ヒアルロン酸 | |
WO2004069230A1 (fr) | Compositions pharmaceutiques a liberation prolongee ou mucoadhesives, contenant un agent actif et un chitosane | |
Angelova et al. | Preparation and properties of modified chitosan films for drug release | |
AU784655B2 (en) | Polysaccharidic esters of N-derivatives of glutamic acid | |
WO2009002299A1 (fr) | Méthode de traitement de vertébrés à sang chaud au moyen de complexes médicamenteux acides de glucosamine exempts d'halogénure | |
CA3050150C (fr) | Formulations de cannabidiol a liberation immediate | |
JP5043364B2 (ja) | 多糖誘導体の製造方法 | |
CA1158159A (fr) | Support de medicament a base d'amidon hydroxyalkyle | |
JP2018507307A (ja) | 水溶性エステル化セルロースエーテル | |
US7662802B2 (en) | Halide-free glucosamine-acidic drug complexes | |
US6933380B2 (en) | Excipients containing low residual solvent and method for producing the same | |
EP1347986B1 (fr) | Sels metalliques de sulfate de glucosamine cristallin et processus de preparation de ces sels | |
US20070259043A1 (en) | Halide-free glucosamine-therapeutic drug salt compositions | |
JP2009519313A5 (fr) | ||
US7388001B1 (en) | Halide-free glucosamine sulfate compositions and methods of preparation | |
US7388000B1 (en) | Halide-free glucosamine phosphate compositions and methods of preparation | |
Khiste et al. | A Review on Applications of Hydroxy Propyl Methyl Cellulose and Natural polymers for the development of modified release drug delivery systems | |
US20070248677A1 (en) | Method for treating warm-blooded vertebrates with a salt of a halide-free glucosamine base and a therapeutic drug | |
US7662803B2 (en) | Method for treating warm-blooded vertebrates with halide-free glucosamine-acidic drug complexes | |
CN101195031A (zh) | 葡萄糖酸改性壳聚糖亲核no供体及其合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20130625 |